Scholar Rock Holding (SRRK) Total Liabilities (2017 - 2026)
Scholar Rock Holding's quarterly Total Liabilities came in at $259.2 million in Q1 2026, up 172.25% year-on-year from $95.2 million in Q1 2025, and up 63.27% quarter-over-quarter from $158.8 million in Q4 2025.
Scholar Rock Holding has reported Total Liabilities for 10 years, with the latest figure at $259.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 172.25% year-over-year to $259.2 million; the trailing twelve-month figure through Mar 2026 stood at $259.2 million (up 172.25% YoY), and the FY2025 full-year result was $158.8 million, up 49.39% from the prior year.
- Total Liabilities for Q1 2026 stood at $259.2 million, up from $158.8 million in the prior quarter.
- The five-year high for Total Liabilities was $259.2 million in Q1 2026, with the low at $82.4 million in Q2 2023.
- Average Total Liabilities over 5 years is $111.3 million, with a median of $95.2 million recorded in 2025.
- Year-over-year, Total Liabilities retreated 26.02% in 2022 and jumped 172.25% in 2026.
- Tracing SRRK's Total Liabilities over 5 years: stood at $97.9 million in 2022, then dropped by 12.37% to $85.8 million in 2023, then rose by 23.85% to $106.3 million in 2024, then soared by 49.39% to $158.8 million in 2025, then soared by 63.27% to $259.2 million in 2026.
- The last three Total Liabilities figures came in at $259.2 million (Q1 2026), $158.8 million (Q4 2025), and $166.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 259.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259.24 Mn |
| Dec 31, 2025 | 158.78 Mn |
| Sep 30, 2025 | 166.72 Mn |
| Jun 30, 2025 | 106.75 Mn |
| Mar 31, 2025 | 95.22 Mn |
| Dec 31, 2024 | 106.29 Mn |
| Sep 30, 2024 | 99.94 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 84.51 Mn |
| Dec 31, 2023 | 85.82 Mn |
| Sep 30, 2023 | 83.02 Mn |
| Jun 30, 2023 | 82.40 Mn |
| Mar 31, 2023 | 86.07 Mn |
| Dec 31, 2022 | 97.93 Mn |
| Sep 30, 2022 | 97.04 Mn |
| Jun 30, 2022 | 94.62 Mn |
| Mar 31, 2022 | 94.66 Mn |
| Dec 31, 2021 | 132.37 Mn |
| Sep 30, 2021 | 111.13 Mn |
| Jun 30, 2021 | 115.40 Mn |
| Mar 31, 2021 | 120.05 Mn |
| Dec 31, 2020 | 127.54 Mn |
| Sep 30, 2020 | 100.44 Mn |
| Jun 30, 2020 | 74.19 Mn |
| Mar 31, 2020 | 77.06 Mn |
| Dec 31, 2019 | 83.48 Mn |
| Sep 30, 2019 | 66.75 Mn |
| Jun 30, 2019 | 67.96 Mn |
| Mar 31, 2019 | 73.46 Mn |
| Dec 31, 2018 | 74.71 Mn |
| Sep 30, 2018 | 6.68 Mn |
| Jun 30, 2018 | 7.37 Mn |
| Mar 31, 2018 | 61.93 Mn |
| Dec 31, 2017 | 5.93 Mn |